Manipulating the mediator: Modulation of the alternative complement pathway C3 convertase in health, disease and therapy

Immunobiology

Volumn 217, Issue 11, 2012, Pages 1057-1066

  Ricklin, Daniel ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Complement; Complement targeted therapeutics; Convertase; Immune evasion; Innate immunity; Regulators of complement activation

Indexed keywords

ALXN 1102; CAB 2; CDX 1135; CDX 135; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C3B; COMPLEMENT INHIBITOR; ECULIZUMAB; MIROCOCEPT; MLN 2222; TA 106; TP 10; TT 30; UNCLASSIFIED DRUG;

BINDING SITE; CARDIOPULMONARY BYPASS; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT DEPOSITION; COMPLEMENT DISORDER; CONFORMATIONAL TRANSITION; DIMERIZATION; GENE MUTATION; GENETIC POLYMORPHISM; HEMOLYTIC UREMIC SYNDROME; HUMAN; IMMUNE EVASION; IMMUNOGENICITY; INFLAMMATION; KIDNEY DISEASE; NONHUMAN; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; STAPHYLOCOCCUS AUREUS; TRANSPLANTATION;

EID: 84866011957     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2012.07.016     Document Type: Review

References (101)

1. Blom A.M., Hallstrom T., Riesbeck K. Complement evasion strategies of pathogens-acquisition of inhibitors and beyond. Mol. Immunol. 2009, 46:2808-2817.
2. Botto M., Kirschfink M., Macor P., Pickering M.C., Wurzner R., Tedesco F. Complement in human diseases: lessons from complement deficiencies. Mol. Immunol. 2009, 46:2774-2783.
3. Bray B.L. Large-scale manufacture of peptide therapeutics by chemical synthesis. Nat. Rev. Drug Discov. 2003, 2:587-593.
4. Castellheim A., Brekke O.L., Espevik T., Harboe M., Mollnes T.E. Innate immune responses to danger signals in systemic inflammatory response syndrome and sepsis. Scand. J. Immunol. 2009, 69:479-491.
5. Chen H., Ricklin D., Hammel M., Garcia B.L., McWhorter W.J., Sfyroera G., Wu Y.Q., Tzekou A., Li S., Geisbrecht B.V., Woods V.L., Lambris J.D. Allosteric inhibition of complement function by a staphylococcal immune evasion protein. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:17621-17626.
6. Chi Z.L., Yoshida T., Lambris J.D., Iwata T. Suppression of drusen formation by compstatin, a peptide inhibitor of complement C3 activation, on cynomolgus monkey with early-onset macular degeneration. Adv. Exp. Med. Biol. 2010, 703:127-135.
7. DiLillo D.J., Pawluczkowycz A.W., Peng W., Kennedy A.D., Beum P.V., Lindorfer M.A., Taylor R.P. Selective and efficient inhibition of the alternative pathway of complement by a mAb that recognizes C3b/iC3b. Mol. Immunol. 2006, 43:1010-1019.
8. Ekdahl K.N., Lambris J.D., Elwing H., Ricklin D., Nilsson P.H., Teramura Y., Nicholls I.A., Nilsson B. Innate immunity activation on biomaterial surfaces: a mechanistic model and coping strategies. Adv. Drug Deliv. Rev. 2011, 63:1042-1050.
9. Fearon D.T., Austen K.F., Ruddy S. Formation of a hemolytically active cellular intermediate by the interaction between properdin factors B and D and the activated third component of complement. J. Exp. Med. 1973, 138:1305-1313.
10. Forneris F., Ricklin D., Wu J., Tzekou A., Wallace R.S., Lambris J.D., Gros P. Structures of C3b in complex with factors B and D give insight into complement convertase formation. Science 2010, 330:1816-1820.
11. Fridkis-Hareli M., Storek M., Mazsaroff I., Risitano A.M., Lundberg A.S., Horvath C.J., Holers V.M. Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases. Blood 2011, 118:4705-4713.
12. Garcia B.L., Ramyar K.X., Ricklin D., Lambris J.D., Geisbrecht B.V. Advances in understanding the structure, function, and mechanism of the SCIN and Efb families of Staphylococcal immune evasion proteins. Adv. Exp. Med. Biol. 2012, 946:113-133.
13. Garcia B.L., Ramyar K.X., Tzekou A., Ricklin D., McWhorter W.J., Lambris J.D., Geisbrecht B.V. Molecular basis for complement recognition and inhibition determined by crystallographic studies of the staphylococcal complement inhibitor (SCIN) bound to C3c and C3b. J. Mol. Biol. 2010, 402:17-29.
14. Garcia B.L., Summers B.J., Lin Z., Ramyar K.X., Ricklin D., Kamath D.V., Fu Z.Q., Lambris J.D., Geisbrecht B.V. Diversity in the C3b [corrected] contact residues and tertiary structures of the staphylococcal complement inhibitor (SCIN) protein family. J. Biol. Chem. 2012, 287:628-640.
15. Gehrs K.M., Jackson J.R., Brown E.N., Allikmets R., Hageman G.S. Complement, age-related macular degeneration and a vision of the future. Arch. Ophthalmol. 2010, 128:349-358.
16. Ghebremariam Y.T., Engelbrecht G., Tyler M., Lotz Z., Govender D., Kotwal G.J., Kahn D. Vaccinia virus complement control protein (VCP) improves kidney structure and function following ischemia/reperfusion injury in rats. J. Surg. Res. 2010, 159:747-754.
17. Gros P., Milder F.J., Janssen B.J. Complement driven by conformational changes. Nat. Rev. Immunol. 2008, 8:48-58.
18. Gustafsson E., Forsberg C., Haraldsson K., Lindman S., Ljung L., Furebring C. Purification of truncated and mutated Chemotaxis Inhibitory Protein of Staphylococcus aureus - an anti-inflammatory protein. Protein Expr. Purif. 2009, 63:95-101.
19. Hammel M., Sfyroera G., Pyrpassopoulos S., Ricklin D., Ramyar K.X., Pop M., Jin Z., Lambris J.D., Geisbrecht B.V. Characterization of Ehp, a secreted complement inhibitory protein from Staphylococcus aureus. J. Biol. Chem. 2007, 282:30051-30061.
20. Hammel M., Sfyroera G., Ricklin D., Magotti P., Lambris J.D., Geisbrecht B.V. A structural basis for complement inhibition by Staphylococcus aureus. Nat. Immunol. 2007, 8:430-437.
21. Harboe M., Ulvund G., Vien L., Fung M., Mollnes T.E. The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation. Clin. Exp. Immunol. 2004, 138:439-446.
22. Haspel N., Ricklin D., Geisbrecht B.V., Kavraki L.E., Lambris J.D. Electrostatic contributions drive the interaction between Staphylococcus aureus protein Efb-C and its complement target C3d. Protein Sci. 2008, 17:1894-1906.
23. Haupt K., Reuter M., van den Elsen J., Burman J., Halbich S., Richter J., Skerka C., Zipfel P.F. The Staphylococcus aureus protein Sbi acts as a complement inhibitor and forms a tripartite complex with host complement Factor H and C3b. PLoS Pathog. 2008, 4:e1000250.
24. Holers V.M. The spectrum of complement alternative pathway-mediated diseases. Immunol. Rev. 2008, 223:300-316.
25. Ioannou A., Dalle Lucca J., Tsokos G.C. Immunopathogenesis of ischemia/reperfusion-associated tissue damage. Clin. Immunol. 2011, 141:3-14.
26. Janssen B.J., Christodoulidou A., McCarthy A., Lambris J.D., Gros P. Structure of C3b reveals conformational changes that underlie complement activity. Nature 2006, 444:213-216.
27. Janssen B.J., Halff E.F., Lambris J.D., Gros P. Structure of compstatin in complex with complement component C3c reveals a new mechanism of complement inhibition. J. Biol. Chem. 2007, 282:29241-29247.
28. Janssen B.J., Huizinga E.G., Raaijmakers H.C., Roos A., Daha M.R., Nilsson-Ekdahl K., Nilsson B., Gros P. Structures of complement component C3 provide insights into the function and evolution of immunity. Nature 2005, 437:505-511.
29. Jha P., Kotwal G.J. Vaccinia complement control protein: multi-functional protein and a potential wonder drug. J. Biosci. 2003, 28:265-271.
30. Jongerius I., Kohl J., Pandey M.K., Ruyken M., van Kessel K.P., van Strijp J.A., Rooijakkers S.H. Staphylococcal complement evasion by various convertase-blocking molecules. J. Exp. Med. 2007, 204:2461-2471.
31. Jongerius I., Puister M., Wu J., Ruyken M., van Strijp J.A., Rooijakkers S.H. Staphylococcal complement inhibitor modulates phagocyte responses by dimerization of convertases. J. Immunol. 2010, 184:420-425.
32. Jongerius I., Ram S., Rooijakkers S. Bacterial complement escape. Adv. Exp. Med. Biol. 2009, 666:32-48.
33. Kajander T., Lehtinen M.J., Hyvarinen S., Bhattacharjee A., Leung E., Isenman D.E., Meri S., Goldman A., Jokiranta T.S. Dual interaction of factor H with C3d and glycosaminoglycans in host-nonhost discrimination by complement. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:2897-2902.
34. Katschke K.J., Stawicki S., Yin J., Steffek M., Xi H., Sturgeon L., Hass P.E., Loyet K.M., Deforge L., Wu Y., van Lookeren Campagne M., Wiesmann C. Structural and functional analysis of a C3b-specific antibody that selectively inhibits the alternative pathway of complement. J. Biol. Chem. 2009, 284:10473-10479.
35. Katschke K.J., Wu P., Ganesan R., Kelley R.F., Mathieu M.A., Hass P.E., Murray J., Kirchhofer D., Wiesmann C., van Lookeren Campagne M. Inhibiting alternative pathway complement activation by targeting the factor D exosite. J. Biol. Chem. 2012, 287:12886-12892.
36. Knerr P.J., Tzekou A., Ricklin D., Qu H., Chen H., van der Donk W.A., Lambris J.D. Synthesis and activity of thioether-containing analogues of the complement inhibitor compstatin. ACS Chem. Biol. 2011, 6:753-760.
37. Kourtzelis I., Markiewski M.M., Doumas M., Rafail S., Kambas K., Mitroulis I., Panagoutsos S., Passadakis P., Vargemezis V., Magotti P., Qu H., Mollnes T.E., Ritis K., Lambris J.D. Complement anaphylatoxin C5a contributes to hemodialysis-associated thrombosis. Blood 2010, 116:631-639.
38. Laarman A., Milder F., van Strijp J., Rooijakkers S. Complement inhibition by gram-positive pathogens: molecular mechanisms and therapeutic implications. J. Mol. Med. (Berl.) 2010, 88:115-120.
39. Laarman A.J., Ruyken M., Malone C.L., van Strijp J.A., Horswill A.R., Rooijakkers S.H. Staphylococcus aureus metalloprotease aureolysin cleaves complement C3 to mediate immune evasion. J. Immunol. 2011, 186:6445-6453.
40. Lambris J.D., Ricklin D., Geisbrecht B.V. Complement evasion by human pathogens. Nat. Rev. Microbiol. 2008, 6:132-142.
41. Lapeyraque A.L., Wagner E., Phan V., Clermont M.J., Merouani A., Fremeaux-Bacchi V., Goodship T.H., Robitaille P. Efficacy of plasma therapy in atypical hemolytic uremic syndrome with complement factor H mutations. Pediatr. Nephrol. 2008, 23:1363-1366.
42. Laursen N.S., Andersen K.R., Braren I., Spillner E., Sottrup-Jensen L., Andersen G.R. Substrate recognition by complement convertases revealed in the C5-cobra venom factor complex. EMBO J. 2011, 30:606-616.
43. Lazar H.L., Keilani T., Fitzgerald C.A., Shapira O.M., Hunter C.T., Shemin R.J., Marsh H.C., Ryan U.S., Group T.P.C.S.S. Beneficial effects of complement inhibition with soluble complement receptor 1 (TP10) during cardiac surgery: is there a gender difference?. Circulation 2007, 116:I83-I88.
44. Le Friec G., Kemper C. Complement: coming full circle. Arch. Immunol. Ther. Exp. (Warsz.) 2009, 57:393-407.
45. Li B., Xi H., Diehl L., Lee W.P., Sturgeon L., Chinn J., Deforge L., Kelley R.F., Wiesmann C., van Lookeren Campagne M., Sidhu S.S. Improving therapeutic efficacy of a complement receptor by structure-based affinity maturation. J. Biol. Chem. 2009, 284:35605-35611.
46. Li J.S., Jaggers J., Anderson P.A. The use of TP10, soluble complement receptor 1, in cardiopulmonary bypass. Expert Rev. Cardiovasc. Ther. 2006, 4:649-654.
47. Licht C., Weyersberg A., Heinen S., Stapenhorst L., Devenge J., Beck B., Waldherr R., Kirschfink M., Zipfel P.F., Hoppe B. Successful plasma therapy for atypical hemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15. Am. J. Kidney Dis. 2005, 45:415-421.
48. Lindorfer M.A., Pawluczkowycz A.W., Peek E.M., Hickman K., Taylor R.P., Parker C.J. A novel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: both complement-mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement. Blood 2010, 115:2283-2291.
49. Magotti P., Ricklin D., Qu H., Wu Y.Q., Kaznessis Y.N., Lambris J.D. Structure-kinetic relationship analysis of the therapeutic complement inhibitor compstatin. J. Mol. Recognit. 2009, 22:495-505.
50. Markiewski M.M., DeAngelis R.A., Lambris J.D. Complexity of complement activation in sepsis. J. Cell. Mol. Med. 2008, 12:2245-2254.
51. Markiewski M.M., Nilsson B., Ekdahl K.N., Mollnes T.E., Lambris J.D. Complement and coagulation: strangers or partners in crime?. Trends Immunol. 2007, 28:184-192.
52. Martinez-Barricarte R., Heurich M., Valdes-Canedo F., Vazquez-Martul E., Torreira E., Montes T., Tortajada A., Pinto S., Lopez-Trascasa M., Morgan B.P., Llorca O., Harris C.L., Rodriguez de Cordoba S. Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. J. Clin. Invest. 2010, 120:3702-3712.
53. Morgan H.P., Schmidt C.Q., Guariento M., Blaum B.S., Gillespie D., Herbert A.P., Kavanagh D., Mertens H.D., Svergun D.I., Johansson C.M., Uhrin D., Barlow P.N., Hannan J.P. Structural basis for engagement by complement factor H of C3b on a self surface. Nat. Struct. Mol. Biol. 2011, 18:463-470.
54. Muller-Eberhard H.J. Molecular organization and function of the complement system. Annu. Rev. Biochem. 1988, 57:321-347.
55. Muller-Eberhard H.J., Gotze O. C3 proactivator convertase and its mode of action. J. Exp. Med. 1972, 135:1003-1008.
56. Mullick J., Kadam A., Sahu A. Herpes and pox viral complement control proteins: the mask of self. Trends Immunol. 2003, 24:500-507.
57. Neher M.D., Weckbach S., Flierl M.A., Huber-Lang M.S., Stahel P.F. Molecular mechanisms of inflammation and tissue injury after major trauma-is complement the " bad guy" ?. J. Biomed. Sci. 2011, 18:90.
58. Nilsson B., Korsgren O., Lambris J.D., Ekdahl K.N. Can cells and biomaterials in therapeutic medicine be shielded from innate immune recognition?. Trends Immunol. 2010, 31:32-38.
59. Nilsson, P.H., Ekdahl, K.N., Magnusson P.U., Hilborn J., Qu H., Iwata, H., Ricklin, D., Hong, J., Lambris, J.D., Nilsson, B., Teramura, Y. Autoregulation of thromboinflammation on biomaterials and cells by a novel therapeutic coating technique, submitted for publication.
60. Nilsson U.R., Nilsson B., Storm K.E., Sjölin-Forsberg G., Hällgren R. Hereditary dysfunction of the third component of complement associated with a systemic lupus erythematosus-like syndrome and meningococcal meningitis. Arthritis Rheum 1992, 35(5):580-586.
61. Nishida N., Walz T., Springer T.A. Structural transitions of complement component C3 and its activation products. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:19737-19742.
62. Oikonomopoulou K., Ricklin D., Ward P.A., Lambris J.D. Interactions between coagulation and complement - their role in inflammation. Semin. Immunopathol. 2012, 34:151-165.
63. Qu H., Magotti P., Ricklin D., Wu E.L., Kourtzelis I., Wu Y.Q., Kaznessis Y.N., Lambris J.D. Novel analogues of the therapeutic complement inhibitor compstatin with significantly improved affinity and potency. Mol. Immunol. 2011, 48:481-489.
64. Qu H., Ricklin D., Bai H., Chen H., Reis E.S., Maciejewski M., Tzekou A., DeAngelis R.A., Resuello R.R.G., Lupu F., Barlow P.N., Lambris J.D. New analogs of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced pharmacokinetic properties. Immunobiology 2012, 10.1016/j.imbio.2012.06.003.
65. Qu H., Ricklin D., Lambris J.D. Recent developments in low molecular weight complement inhibitors. Mol. Immunol. 2009, 47:185-195.
66. Reis E.S., Falcao D.A., Isaac L. Clinical aspects and molecular basis of primary deficiencies of complement component C3 and its regulatory proteins factor I and factor H. Scand. J. Immunol. 2006, 63:155-168.
67. Ricklin D., Hajishengallis G., Yang K., Lambris J.D. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 2010, 11:785-797.
68. Ricklin D., Lambris J.D. Complement-targeted therapeutics. Nat. Biotechnol. 2007, 25:1265-1275.
69. Ricklin D., Lambris J.D. Compstatin: a complement inhibitor on its way to clinical application. Adv. Exp. Med. Biol. 2008, 632:273-292.
70. Ricklin D., Lambris J.D. Progress and trends in complement therapeutics. Adv. Exp. Med. Biol. 2012, 10.1007/978-1-4614-4118-2_1.
71. Ricklin D., Ricklin-Lichtsteiner S.K., Markiewski M.M., Geisbrecht B.V., Lambris J.D. Cutting edge: members of the Staphylococcus aureus extracellular fibrinogen-binding protein family inhibit the interaction of C3d with complement receptor 2. J. Immunol. 2008, 181:7463-7467.
72. Ricklin D., Tzekou A., Garcia B.L., Hammel M., McWhorter W.J., Sfyroera G., Wu Y.Q., Holers V.M., Herbert A.P., Barlow P.N., Geisbrecht B.V., Lambris J.D. A molecular insight into complement evasion by the staphylococcal complement inhibitor protein family. J. Immunol. 2009, 183:2565-2574.
73. Risitano A.M., Notaro R., Pascariello C., Sica M., Del Vecchio L., Horvath C.J., Fridkis-Hareli M., Selleri C., Lindorfer M.A., Taylor R.P., Luzzatto L., Holers V.M. The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment. Blood 2012, 119:6307-6316.
74. Risitano A.M., Perna F., Selleri C. Achievements and limitations of complement inhibition by eculizumab in paroxysmal nocturnal hemoglobinuria: the role of complement component 3. Mini Rev. Med. Chem. 2011, 11:528-535.
75. Rodriguez de Cordoba S., Harris C.L., Morgan B.P., Llorca O. Lessons from functional and structural analyses of disease-associated genetic variants in the complement alternative pathway. Biochim. Biophys. Acta 2011, 1812:12-22.
76. Rooijakkers S.H., Wu J., Ruyken M., van Domselaar R., Planken K.L., Tzekou A., Ricklin D., Lambris J.D., Janssen B.J., van Strijp J.A., Gros P. Structural and functional implications of the alternative complement pathway C3 convertase stabilized by a staphylococcal inhibitor. Nat. Immunol. 2009, 10:721-727.
77. Roversi P., Johnson S., Caesar J.J., McLean F., Leath K.J., Tsiftsoglou S.A., Morgan B.P., Harris C.L., Sim R.B., Lea S.M. Structural basis for complement factor I control and its disease-associated sequence polymorphisms. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:12839-12844.
78. Sacks S.H., Zhou W. The role of complement in the early immune response to transplantation. Nat. Rev. Immunol. 2012, 12:431-442.
79. Schmidt, C.Q., Bai, H., Lin, Z., Risitano, A.M., Barlow, P.N., Ricklin, D., Lambris, J.D. Rational engineering of a novel complement regulator affords triple targeting of cells and controls innate immunity in disease condition, in preparation.
80. Schmidt C.Q., Slingsby F.C., Richards A., Barlow P.N. Production of biologically active complement factor H in therapeutically useful quantities. Protein Expr. Purif. 2011, 76:254-263.
81. Schneider M.C., Exley R.M., Chan H., Feavers I., Kang Y.H., Sim R.B., Tang C.M. Functional significance of factor H binding to Neisseria meningitidis. J. Immunol. 2006, 176:7566-7575.
82. Schneider M.C., Prosser B.E., Caesar J.J., Kugelberg E., Li S., Zhang Q., Quoraishi S., Lovett J.E., Deane J.E., Sim R.B., Roversi P., Johnson S., Tang C.M., Lea S.M. Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates. Nature 2009, 458:890-893.
83. Schreiber R.D., Pangburn M.K., Lesavre P.H., Muller-Eberhard H.J. Initiation of the alternative pathway of complement: recognition of activators by bound C3b and assembly of the entire pathway from six isolated proteins. Proc. Natl. Acad. Sci. U.S.A. 1978, 75:3948-3952.
84. Schuster M.C., Ricklin D., Papp K., Molnar K.S., Coales S.J., Hamuro Y., Sfyroera G., Chen H., Winters M.S., Lambris J.D. Dynamic structural changes during complement C3 activation analyzed by hydrogen/deuterium exchange mass spectrometry. Mol. Immunol. 2008, 45:3142-3151.
85. Serruto D., Rappuoli R., Scarselli M., Gros P., van Strijp J.A. Molecular mechanisms of complement evasion: learning from staphylococci and meningococci. Nat. Rev. Microbiol. 2010, 8:393-399.
86. Sfyroera G., Ricklin D., Chen H., Nilsson-Ekdahl K., Nilsson B., Wu E.L., Kaznessis Y.N., Lambris J.D. Impaired ability of complement activation via the alternative pathway C3 convertase caused by a single-point mutation in the beta chain of C3. Mol. Immunol. 2010, 47:2289.
87. Sharp J.A., Echague C.G., Hair P.S., Ward M.D., Nyalwidhe J.O., Geoghegan J.A., Foster T.J., Cunnion K.M. Staphylococcus aureus surface protein SdrE binds complement regulator factor H as an immune evasion tactic. PLoS One 2012, 7:e38407.
88. Silasi-Mansat R., Zhu H., Popescu N.I., Peer G., Sfyroera G., Magotti P., Ivanciu L., Lupu C., Mollnes T.E., Taylor F.B., Kinasewitz G., Lambris J.D., Lupu F. Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of Escherichia coli sepsis. Blood 2010, 116:1002-1010.
89. Smith E.J., Visai L., Kerrigan S.W., Speziale P., Foster T.J. The Sbi protein is a multifunctional immune evasion factor of Staphylococcus aureus. Infect. Immun. 2011, 79:3801-3809.
90. Smith R.A. Targeting anticomplement agents. Biochem. Soc. Trans. 2002, 30:1037-1041.
91. Thurman J.M., Kraus D.M., Girardi G., Hourcade D., Kang H.J., Royer P.A., Mitchell L.M., Giclas P.C., Salmon J., Gilkeson G., Holers V.M. A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice. Mol. Immunol. 2005, 42:87-97.
92. van der Pals J., Koul S., Andersson P., Gotberg M., Ubachs J.F., Kanski M., Arheden H., Olivecrona G.K., Larsson B., Erlinge D. Treatment with the C5a receptor antagonist ADC-1004 reduces myocardial infarction in a porcine ischemia-reperfusion model. BMC Cardiovasc. Disord. 2010, 10:45.
93. Veerhuis R., Nielsen H.M., Tenner A.J. Complement in the brain. Mol. Immunol. 2011, 48:1592-1603.
94. Vlieghe P., Lisowski V., Martinez J., Khrestchatisky M. Synthetic therapeutic peptides: science and market. Drug Discov. Today 2010, 15:40-56.
95. Ward P.A., Gao H. Sepsis, complement and the dysregulated inflammatory response. J. Cell. Mol. Med. 2009, 13:4154-4160.
96. Weismann D., Hartvigsen K., Lauer N., Bennett K.L., Scholl H.P., Charbel Issa P., Cano M., Brandstatter H., Tsimikas S., Skerka C., Superti-Furga G., Handa J.T., Zipfel P.F., Witztum J.L., Binder C.J. Complement factor H binds malondialdehyde epitopes and protects from oxidative stress. Nature 2011, 478:76-81.
97. Wells J.A., McClendon C.L. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 2007, 450:1001-1009.
98. Wiesmann C., Katschke K.J., Yin J., Helmy K.Y., Steffek M., Fairbrother W.J., McCallum S.A., Embuscado L., DeForge L., Hass P.E., van Lookeren Campagne M. Structure of C3b in complex with CRIg gives insights into regulation of complement activation. Nature 2006, 444:217-220.
99. Wu J., Wu Y.Q., Ricklin D., Janssen B.J., Lambris J.D., Gros P. Structure of complement fragment C3b-factor H and implications for host protection by complement regulators. Nat. Immunol. 2009, 10:728-733.
100. Wu Y.Q., Qu H., Sfyroera G., Tzekou A., Kay B.K., Nilsson B., Nilsson Ekdahl K., Ricklin D., Lambris J.D. Protection of nonself surfaces from complement attack by factor H-binding peptides: implications for therapeutic medicine. J. Immunol. 2011, 186:4269-4277.
101. Yehoshua Z., Rosenfeld P.J., Albini T.A. Current clinical trials in dry AMD and the definition of appropriate clinical outcome measures. Semin. Ophthalmol. 2011, 26:167-180.